Effectiveness of janus kinase inhibitors in relapsing giant cell arteritis in real-world clinical practice and review of the literature.
Javier LoriceraToluwalase TofadeDiana Prieto-PeñaSusana Romero-YusteEugenio de MiguelAnne Riveros-FrutosIván Ferraz-AmaroEztizen LabradorOlga MaizElena BecerraJavier NarváezEva Galíndez-AgirregoikoaIsmael González-FernándezAna Urruticoechea-AranaÁngel Ramos-CalvoFernando López-GutiérrezSantos CastañedaSebastian H UnizonyRicardo Blanco-AlonsoPublished in: Arthritis research & therapy (2024)
This real-world analysis and literature review suggest that JAKi could be effective in GCA, including in patients failing established glucocorticoid-sparing therapies such as tocilizumab and methotrexate. A phase III randomized controlled trial of upadacitinib is currently ongoing (ClinicalTrials.gov ID NCT03725202).
Keyphrases
- randomized controlled trial
- phase iii
- giant cell
- clinical practice
- end stage renal disease
- multiple sclerosis
- clinical trial
- open label
- rheumatoid arthritis
- ejection fraction
- newly diagnosed
- study protocol
- chronic kidney disease
- systematic review
- case report
- peritoneal dialysis
- disease activity
- low dose
- double blind
- patient reported
- rheumatoid arthritis patients
- placebo controlled
- data analysis
- meta analyses